Literature DB >> 12973523

Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries.

Alvaro Moncayo1.   

Abstract

Chagas disease, named after Carlos Chagas who first described it in 1909, exists only on the American Continent. It is caused by a parasite, Trypanosoma cruzi, transmitted to humans by blood-sucking triatomine bugs and by blood transfusion. Chagas disease has two successive phases, acute and chronic. The acute phase lasts 6 to 8 weeks. After several years of starting the chronic phase, 20% to 35% of the infected individuals, depending on the geographical area will develop irreversible lesions of the autonomous nervous system in the heart, esophagus, colon and the peripheral nervous system. Data on the prevalence and distribution of Chagas disease improved in quality during the 1980's as a result of the demographically representative cross-sectional studies carried out in countries where accurate information was not available. A group of experts met in Bras lia in 1979 and devised standard protocols to carry out countrywide prevalence studies on human T. cruzi infection and triatomine house infestation. Thanks to a coordinated multi-country program in the Southern Cone countries the transmission of Chagas disease by vectors and by blood transfusion has been interrupted in Uruguay in1997, in Chile in 1999, and in 8 of the 12 endemic states of Brazil in 2000 and so the incidence of new infections by T. cruzi in the whole continent has decreased by 70%. Similar control multi-country initiatives have been launched in the Andean countries and in Central America and rapid progress has been recorded to ensure the interruption of the transmission of Chagas disease by 2005 as requested by a Resolution of the World Health Assembly approved in 1998. The cost-benefit analysis of the investments of the vector control program in Brazil indicate that there are savings of US$17 in medical care and disabilities for each dollar spent on prevention, showing that the program is a health investment with good return. Since the inception in 1979 of the Steering Committee on Chagas Disease of the Special Program for Research and Training in Tropical Diseases of the World Health Organization (TDR), the objective was set to promote and finance research aimed at the development of new methods and tools to control this disease. The well known research institutions in Latin America were the key elements of a world wide network of laboratories that received - on a competitive basis - financial support for projects in line with the priorities established. It is presented the time line of the different milestones that were answering successively and logically the outstanding scientific questions identified by the Scientific Working Group in 1978 and that influenced the development and industrial production of practical solutions for diagnosis of the infection and disease control.

Entities:  

Mesh:

Year:  2003        PMID: 12973523     DOI: 10.1590/s0074-02762003000500001

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  77 in total

Review 1.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Synthesis of PEGylated lactose analogs for inhibition studies on T.cruzi trans-sialidase.

Authors:  M Eugenia Giorgi; Laura Ratier; Rosalía Agusti; Alberto C C Frasch; Rosa M de Lederkremer
Journal:  Glycoconj J       Date:  2010-07-20       Impact factor: 2.916

3.  Chagasic megacolon associated with Trypanosoma cruzi I in a Colombian patient.

Authors:  Oscar Flórez; Jhonatan Esper; Sergio Higuera; María Fernanda Barraza; Huxley Braulio Cabrera; Julio César Mantilla; Clara Isabel González Rugeles
Journal:  Parasitol Res       Date:  2010-05-26       Impact factor: 2.289

Review 4.  The elimination of Chagas' disease from Brazil.

Authors:  E Massad
Journal:  Epidemiol Infect       Date:  2007-12-04       Impact factor: 2.451

5.  Evidence of Trypanosoma cruzi II infection in Colombian chagasic patients.

Authors:  German Zafra; Julio Cesar Mantilla; Helder Magno Valadares; Andrea Mara Macedo; Clara Isabel González
Journal:  Parasitol Res       Date:  2008-06-04       Impact factor: 2.289

6.  The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases.

Authors:  Pere P Simarro; Giuliano Cecchi; Massimo Paone; José R Franco; Abdoulaye Diarra; José A Ruiz; Eric M Fèvre; Fabrice Courtin; Raffaele C Mattioli; Jean G Jannin
Journal:  Int J Health Geogr       Date:  2010-11-01       Impact factor: 3.918

7.  Human trypanosomiasis in the eastern region of the Panama Province: new endemic areas for Chagas disease.

Authors:  José E Calzada; Vanesa Pineda; Juan D Garisto; Franklyn Samudio; Ana Maria Santamaria; Azael Saldaña
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

8.  Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Authors:  Momar Ndao; Christian Beaulieu; W Cameron Black; Elise Isabel; Fabio Vasquez-Camargo; Milli Nath-Chowdhury; Frédéric Massé; Christophe Mellon; Nathalie Methot; Deborah A Nicoll-Griffith
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

9.  Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina.

Authors:  Mirta C Remesar; Cecilia Gamba; Ivana F Colaianni; Mónica Puppo; Paula A Sartor; Edward L Murphy; Torsten B Neilands; María A Ridolfi; M Susana Leguizamón; Silvina Kuperman; Ana E Del Pozo
Journal:  Transfusion       Date:  2009-11       Impact factor: 3.157

10.  Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice.

Authors:  Gabriel Melo de Oliveira; Tshaca Mahatma da Silva; Wanderson Silva Batista; Marcello Franco; Nestor Schor
Journal:  Parasitol Res       Date:  2009-09-26       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.